Argent BioPharma Limited
RGT.L · LSE
6/30/2024 | 12/31/2023 | 6/30/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Revenue | £0 | £0 | £0 | £1 |
| % Growth | -52% | -15.7% | -74.6% | – |
| Cost of Goods Sold | £0 | £0 | £0 | £1 |
| Gross Profit | -£0 | £0 | £0 | £1 |
| % Margin | -129.1% | 12.1% | 16.2% | 46.3% |
| R&D Expenses | £2 | £0 | £2 | £0 |
| G&A Expenses | £5 | £4 | £3 | £4 |
| SG&A Expenses | £5 | £4 | £3 | £4 |
| Sales & Mktg Exp. | £0 | £0 | £0 | £0 |
| Other Operating Expenses | -£1 | -£0 | -£0 | £3 |
| Operating Expenses | £6 | £3 | £5 | £7 |
| Operating Income | -£6 | -£3 | -£5 | -£6 |
| % Margin | -3,792.7% | -941.2% | -1,198.2% | -420.1% |
| Other Income/Exp. Net | £0 | -£1 | -£1 | £0 |
| Pre-Tax Income | -£6 | -£4 | -£5 | -£6 |
| Tax Expense | £0 | £0 | £0 | £0 |
| Net Income | -£6 | -£4 | -£5 | -£6 |
| % Margin | -3,585.8% | -1,180.3% | -1,371.4% | -408.7% |
| EPS | -0.11 | -0.16 | -1.59 | -2.37 |
| % Growth | 31.3% | 89.9% | 32.9% | – |
| EPS Diluted | -0.11 | -0.16 | -1.58 | -2.37 |
| Weighted Avg Shares Out | 51 | 23 | 3 | 3 |
| Weighted Avg Shares Out Dil | 51 | 23 | 3 | 3 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £0 | -£0 | £0 |
| Interest Expense | £0 | £0 | £0 | £0 |
| Depreciation & Amortization | £0 | £0 | £0 | £0 |
| EBITDA | -£5 | -£4 | -£4 | -£4 |
| % Margin | -3,243.3% | -1,252.6% | -952.6% | -291.5% |